Induction of CYP1A1, a widely used biomarker for AhR-active compounds and other Ah-responsive genes, was minimal to non-detectable in a panel of GBM cell lines treated with OME and ESO (Figure 2D). This evidence concerns the gene CYP1A1 and glioblastoma.